董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Songjiang Ma | -- | President and Director | -- | 18.09万美元 | 736.26 | 2025-08-18 |
| Ping Zhang | 男 | Executive Chair, Interim Chief Executive Officer | 51 | 409.66万美元 | 0.58 | 2025-08-18 |
| Rodney L. Nussbaum | -- | Independent Director | -- | 21.42万美元 | 1.22 | 2025-08-18 |
| Thomas Eastling | -- | Director | -- | 20.62万美元 | 97.25 | 2025-08-18 |
| Gordon G. Carmichael | -- | Independent Director | -- | 20.82万美元 | 1.22 | 2025-08-18 |
| David M. Epstein | -- | Independent Director | -- | 21.22万美元 | 1.16 | 2025-08-18 |
| Renate Parry | -- | Independent Director | -- | 21.92万美元 | 1.22 | 2025-08-18 |
| Dan Weng | 男 | Director | 62 | 38.31万美元 | 未持股 | 2025-08-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Songjiang Ma | -- | President and Director | -- | 18.09万美元 | 736.26 | 2025-08-18 |
| Ping Zhang | 男 | Executive Chair, Interim Chief Executive Officer | 51 | 409.66万美元 | 0.58 | 2025-08-18 |
| Han Ying | -- | Senior Vice President, Science | -- | 35.33万美元 | 0.06 | 2025-08-18 |
| Ruoyu Chen | -- | Chief Financial Officer and Principal Accounting Officer | -- | 28.56万美元 | 97.25 | 2025-08-18 |
| Weiguo Ye | -- | Chief Operating Officer | -- | 502.37万美元 | 167.76 | 2025-08-18 |
董事简历
中英对照 | 中文 | 英文- Songjiang Ma
-
马松江是中国公民。
Songjiang Ma is a citizen of China. - 马松江是中国公民。
- Songjiang Ma is a citizen of China.
- Ping Zhang
-
张平，自2025年1月起担任公司董事，自2025年3月起担任董事会（“董事会”）执行主席。亦自2025年4月起担任公司多数间接拥有的附属公司北京大地药业有限公司（d/b/a Gyre Pharmaceuticals Co.，Ltd.）的董事长及法定代表人，并自2025年3月起担任公司母公司GNI Group Ltd.（TSE：2160）（“GNI Japan”）的董事及执行官。张先生于2025年1月至2025年3月担任公司首席董事。张先生自2018年起担任私募股权投资公司String Capital Management Co.，Limited的管理合伙人。2015年至2018年，他在永旺人寿保险有限公司担任私募股权和风险投资主管。在此之前，2011年至2015年，他领导了日本亚洲投资有限公司的专注于中国的基金，专注于日本和中国之间的跨境投资。从2008年到2010年，张先生是总部位于纽约的中型收购基金AEA Investors LP的唯一中国大陆董事总经理和合伙人。2004年至2008年间，他在中国成立并领导了三菱日联金融集团的投资银行和风险投资部门，担任其首席执行官。在其职业生涯的早期，他曾在三井物产和伊藤忠商事任职。张先生目前还担任亚星客车股份有限公司（TSE：8946）的董事。他拥有复旦大学高分子科学学士学位和芝加哥大学布斯商学院金融硕士学位。
Ping Zhang,has served as a director of the Company since January 2025 and as Executive Chair of the board of directors (the "Board") since March 2025. He has also served as Chairman and legal representative of the Company's majority, indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) since April 2025, and as a director and an executive officer of the Company's parent company, GNI Group Ltd. (TSE: 2160) ("GNI Japan"), since March 2025. Mr. Zhang was the Lead Director of the Company from January 2025 to March 2025. Mr. Zhang has served as a Managing Partner at String Capital Management Co., Limited, a private equity investment firm, since 2018. From 2015 to 2018, he served as Head of Private Equity and Venture Capital Investments at AEON Life Insurance Company, Ltd. Prior to that, from 2011 to 2015, he led the China-focused funds of Japan Asia Investment Co., Ltd., focusing on cross-border investments between Japan and China. From 2008 to 2010, Mr. Zhang was the only mainland Chinese Managing Director and Partner at AEA Investors LP, a New York-based mid-cap buyout fund. Between 2004 and 2008, he established and led the investment banking and venture capital arm of Mitsubishi UFJ Financial Group in China, serving as its Chief Executive Officer. Earlier in his career, he held roles at Mitsui & Co. and Itochu Corporation. Mr. Zhang also currently serves as a director of Asian Star Co. (TSE: 8946). He holds a B.S. in Polymer Science from Fudan University and his M.B.A. in Finance from the University of Chicago Booth School of Business. - 张平，自2025年1月起担任公司董事，自2025年3月起担任董事会（“董事会”）执行主席。亦自2025年4月起担任公司多数间接拥有的附属公司北京大地药业有限公司（d/b/a Gyre Pharmaceuticals Co.，Ltd.）的董事长及法定代表人，并自2025年3月起担任公司母公司GNI Group Ltd.（TSE：2160）（“GNI Japan”）的董事及执行官。张先生于2025年1月至2025年3月担任公司首席董事。张先生自2018年起担任私募股权投资公司String Capital Management Co.，Limited的管理合伙人。2015年至2018年，他在永旺人寿保险有限公司担任私募股权和风险投资主管。在此之前，2011年至2015年，他领导了日本亚洲投资有限公司的专注于中国的基金，专注于日本和中国之间的跨境投资。从2008年到2010年，张先生是总部位于纽约的中型收购基金AEA Investors LP的唯一中国大陆董事总经理和合伙人。2004年至2008年间，他在中国成立并领导了三菱日联金融集团的投资银行和风险投资部门，担任其首席执行官。在其职业生涯的早期，他曾在三井物产和伊藤忠商事任职。张先生目前还担任亚星客车股份有限公司（TSE：8946）的董事。他拥有复旦大学高分子科学学士学位和芝加哥大学布斯商学院金融硕士学位。
- Ping Zhang,has served as a director of the Company since January 2025 and as Executive Chair of the board of directors (the "Board") since March 2025. He has also served as Chairman and legal representative of the Company's majority, indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) since April 2025, and as a director and an executive officer of the Company's parent company, GNI Group Ltd. (TSE: 2160) ("GNI Japan"), since March 2025. Mr. Zhang was the Lead Director of the Company from January 2025 to March 2025. Mr. Zhang has served as a Managing Partner at String Capital Management Co., Limited, a private equity investment firm, since 2018. From 2015 to 2018, he served as Head of Private Equity and Venture Capital Investments at AEON Life Insurance Company, Ltd. Prior to that, from 2011 to 2015, he led the China-focused funds of Japan Asia Investment Co., Ltd., focusing on cross-border investments between Japan and China. From 2008 to 2010, Mr. Zhang was the only mainland Chinese Managing Director and Partner at AEA Investors LP, a New York-based mid-cap buyout fund. Between 2004 and 2008, he established and led the investment banking and venture capital arm of Mitsubishi UFJ Financial Group in China, serving as its Chief Executive Officer. Earlier in his career, he held roles at Mitsui & Co. and Itochu Corporation. Mr. Zhang also currently serves as a director of Asian Star Co. (TSE: 8946). He holds a B.S. in Polymer Science from Fudan University and his M.B.A. in Finance from the University of Chicago Booth School of Business.
- Rodney L. Nussbaum
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Thomas Eastling
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Gordon G. Carmichael
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- David M. Epstein
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Renate Parry
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Dan Weng
-
翁丹，自2018年4月起担任专科肿瘤合同研究机构Medelis，Inc.总裁兼首席执行官。2013年10月至2017年6月，翁博士担任全球合同研究机构EPS Holdings，Inc.旗下EPS International Holding Co.的董事长、总裁兼首席执行官。在EPS任职期间，翁博士通过在亚洲的有机和并购监督了显着的增长，并在公司战略和投资者关系方面发挥了积极作用。在加入Medelis和EPS之前，翁博士曾在多个国际合同研究机构担任高管职务，包括担任ROW、Medpace，Inc.副总裁、ROW、ICON PLC总裁、远东地区高级总监、PharmaNet Development Group和昆泰转化公司中国首席代表。翁博士还曾在哈佛医学院、麻省总医院和加州大学担任研究职务。翁博士在中国同济医科大学获得医学博士学位，并拥有利兹大学健康规划、政策和管理硕士学位。中国科学院心理研究所人类心理学专业本科毕业。
Dan Weng,has served as President and Chief Executive Officer of Medelis, Inc., a specialty oncology contract research organization, since April 2018. From October 2013 to June 2017, Dr. Weng was Chairman, President and Chief Executive Officer of EPS International Holding Co., a subsidiary of EPS Holdings, Inc., a global contract research organization. During his tenure at EPS, Dr. Weng oversaw significant growth, organically and through M&A in Asia, and had an active role in corporate strategy and investor relations. Prior to Medelis and EPS, Dr. Weng held executive positions at various international contract research organizations, including as Vice President of ROW, Medpace, Inc., President of ROW, ICON Plc, Senior Director of Far East, PharmaNet Development Group and Chief Representative of China, Quintiles Translational Corp. Dr. Weng has also held research positions at Harvard Medical School, Massachusetts General Hospital and the University of California. Dr. Weng obtained his M.D. from the Tongji Medical University, China, and holds an M.A. in Health Planning, Policy and Management from the University of Leeds. He received his undergraduate degree in human psychology from the Psychology Institute of Sino-Academy of Sciences. - 翁丹，自2018年4月起担任专科肿瘤合同研究机构Medelis，Inc.总裁兼首席执行官。2013年10月至2017年6月，翁博士担任全球合同研究机构EPS Holdings，Inc.旗下EPS International Holding Co.的董事长、总裁兼首席执行官。在EPS任职期间，翁博士通过在亚洲的有机和并购监督了显着的增长，并在公司战略和投资者关系方面发挥了积极作用。在加入Medelis和EPS之前，翁博士曾在多个国际合同研究机构担任高管职务，包括担任ROW、Medpace，Inc.副总裁、ROW、ICON PLC总裁、远东地区高级总监、PharmaNet Development Group和昆泰转化公司中国首席代表。翁博士还曾在哈佛医学院、麻省总医院和加州大学担任研究职务。翁博士在中国同济医科大学获得医学博士学位，并拥有利兹大学健康规划、政策和管理硕士学位。中国科学院心理研究所人类心理学专业本科毕业。
- Dan Weng,has served as President and Chief Executive Officer of Medelis, Inc., a specialty oncology contract research organization, since April 2018. From October 2013 to June 2017, Dr. Weng was Chairman, President and Chief Executive Officer of EPS International Holding Co., a subsidiary of EPS Holdings, Inc., a global contract research organization. During his tenure at EPS, Dr. Weng oversaw significant growth, organically and through M&A in Asia, and had an active role in corporate strategy and investor relations. Prior to Medelis and EPS, Dr. Weng held executive positions at various international contract research organizations, including as Vice President of ROW, Medpace, Inc., President of ROW, ICON Plc, Senior Director of Far East, PharmaNet Development Group and Chief Representative of China, Quintiles Translational Corp. Dr. Weng has also held research positions at Harvard Medical School, Massachusetts General Hospital and the University of California. Dr. Weng obtained his M.D. from the Tongji Medical University, China, and holds an M.A. in Health Planning, Policy and Management from the University of Leeds. He received his undergraduate degree in human psychology from the Psychology Institute of Sino-Academy of Sciences.
高管简历
中英对照 | 中文 | 英文- Songjiang Ma
马松江是中国公民。
Songjiang Ma is a citizen of China.- 马松江是中国公民。
- Songjiang Ma is a citizen of China.
- Ping Zhang
张平，自2025年1月起担任公司董事，自2025年3月起担任董事会（“董事会”）执行主席。亦自2025年4月起担任公司多数间接拥有的附属公司北京大地药业有限公司（d/b/a Gyre Pharmaceuticals Co.，Ltd.）的董事长及法定代表人，并自2025年3月起担任公司母公司GNI Group Ltd.（TSE：2160）（“GNI Japan”）的董事及执行官。张先生于2025年1月至2025年3月担任公司首席董事。张先生自2018年起担任私募股权投资公司String Capital Management Co.，Limited的管理合伙人。2015年至2018年，他在永旺人寿保险有限公司担任私募股权和风险投资主管。在此之前，2011年至2015年，他领导了日本亚洲投资有限公司的专注于中国的基金，专注于日本和中国之间的跨境投资。从2008年到2010年，张先生是总部位于纽约的中型收购基金AEA Investors LP的唯一中国大陆董事总经理和合伙人。2004年至2008年间，他在中国成立并领导了三菱日联金融集团的投资银行和风险投资部门，担任其首席执行官。在其职业生涯的早期，他曾在三井物产和伊藤忠商事任职。张先生目前还担任亚星客车股份有限公司（TSE：8946）的董事。他拥有复旦大学高分子科学学士学位和芝加哥大学布斯商学院金融硕士学位。
Ping Zhang,has served as a director of the Company since January 2025 and as Executive Chair of the board of directors (the "Board") since March 2025. He has also served as Chairman and legal representative of the Company's majority, indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) since April 2025, and as a director and an executive officer of the Company's parent company, GNI Group Ltd. (TSE: 2160) ("GNI Japan"), since March 2025. Mr. Zhang was the Lead Director of the Company from January 2025 to March 2025. Mr. Zhang has served as a Managing Partner at String Capital Management Co., Limited, a private equity investment firm, since 2018. From 2015 to 2018, he served as Head of Private Equity and Venture Capital Investments at AEON Life Insurance Company, Ltd. Prior to that, from 2011 to 2015, he led the China-focused funds of Japan Asia Investment Co., Ltd., focusing on cross-border investments between Japan and China. From 2008 to 2010, Mr. Zhang was the only mainland Chinese Managing Director and Partner at AEA Investors LP, a New York-based mid-cap buyout fund. Between 2004 and 2008, he established and led the investment banking and venture capital arm of Mitsubishi UFJ Financial Group in China, serving as its Chief Executive Officer. Earlier in his career, he held roles at Mitsui & Co. and Itochu Corporation. Mr. Zhang also currently serves as a director of Asian Star Co. (TSE: 8946). He holds a B.S. in Polymer Science from Fudan University and his M.B.A. in Finance from the University of Chicago Booth School of Business.- 张平，自2025年1月起担任公司董事，自2025年3月起担任董事会（“董事会”）执行主席。亦自2025年4月起担任公司多数间接拥有的附属公司北京大地药业有限公司（d/b/a Gyre Pharmaceuticals Co.，Ltd.）的董事长及法定代表人，并自2025年3月起担任公司母公司GNI Group Ltd.（TSE：2160）（“GNI Japan”）的董事及执行官。张先生于2025年1月至2025年3月担任公司首席董事。张先生自2018年起担任私募股权投资公司String Capital Management Co.，Limited的管理合伙人。2015年至2018年，他在永旺人寿保险有限公司担任私募股权和风险投资主管。在此之前，2011年至2015年，他领导了日本亚洲投资有限公司的专注于中国的基金，专注于日本和中国之间的跨境投资。从2008年到2010年，张先生是总部位于纽约的中型收购基金AEA Investors LP的唯一中国大陆董事总经理和合伙人。2004年至2008年间，他在中国成立并领导了三菱日联金融集团的投资银行和风险投资部门，担任其首席执行官。在其职业生涯的早期，他曾在三井物产和伊藤忠商事任职。张先生目前还担任亚星客车股份有限公司（TSE：8946）的董事。他拥有复旦大学高分子科学学士学位和芝加哥大学布斯商学院金融硕士学位。
- Ping Zhang,has served as a director of the Company since January 2025 and as Executive Chair of the board of directors (the "Board") since March 2025. He has also served as Chairman and legal representative of the Company's majority, indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) since April 2025, and as a director and an executive officer of the Company's parent company, GNI Group Ltd. (TSE: 2160) ("GNI Japan"), since March 2025. Mr. Zhang was the Lead Director of the Company from January 2025 to March 2025. Mr. Zhang has served as a Managing Partner at String Capital Management Co., Limited, a private equity investment firm, since 2018. From 2015 to 2018, he served as Head of Private Equity and Venture Capital Investments at AEON Life Insurance Company, Ltd. Prior to that, from 2011 to 2015, he led the China-focused funds of Japan Asia Investment Co., Ltd., focusing on cross-border investments between Japan and China. From 2008 to 2010, Mr. Zhang was the only mainland Chinese Managing Director and Partner at AEA Investors LP, a New York-based mid-cap buyout fund. Between 2004 and 2008, he established and led the investment banking and venture capital arm of Mitsubishi UFJ Financial Group in China, serving as its Chief Executive Officer. Earlier in his career, he held roles at Mitsui & Co. and Itochu Corporation. Mr. Zhang also currently serves as a director of Asian Star Co. (TSE: 8946). He holds a B.S. in Polymer Science from Fudan University and his M.B.A. in Finance from the University of Chicago Booth School of Business.
- Han Ying
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Ruoyu Chen
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Weiguo Ye
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介